Levofloxacin use in the elderly: Focus on pneumonia

Aging Health

Volumn 2, Issue 3, 2006, Pages 371-382

  Cappelletty, Diane M ^a   Zervos, Mark ^b,c  

^a MEDICAL COLLEGE OF OHIO   (United States)

^b HENRY FORD HEALTH SYSTEM   (United States)

^c WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Community acquired pneumonia; Fluoroquinolones; Levofloxacin; Ofloxacin

Indexed keywords

ALUMINUM; ANTACID AGENT; AZITHROMYCIN; CALCIUM; CEFOTAXIME; CEFTRIAXONE; CEPHALOSPORIN; CILASTATIN PLUS IMIPENEM; DNA TOPOISOMERASE; DNA TOPOISOMERASE (ATP HYDROLYSING); ERYTHROMYCIN; GATIFLOXACIN; GLUCOSE; IRON; LEVOFLOXACIN; MACROLIDE; MAGNESIUM; METICILLIN; MOXIFLOXACIN; OFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; WARFARIN;

ABDOMINAL INFECTION; ACINETOBACTER; AGING; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; AREA UNDER THE CURVE; ARTICLE; ATRIOVENTRICULAR BLOCK; BACTERIAL PNEUMONIA; BACTERICIDAL ACTIVITY; CHLAMYDOPHILA PNEUMONIAE; CHRONIC BRONCHITIS; CLINICAL TRIAL; COMMUNITY ACQUIRED PNEUMONIA; CONCENTRATION RESPONSE; CONFUSION; CONSTIPATION; DIARRHEA; DIZZINESS; DRUG ACTIVITY; DRUG APPROVAL; DRUG CHOICE; DRUG DISTRIBUTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG ELIMINATION; DRUG ERUPTION; DRUG EXCRETION; DRUG HALF LIFE; DRUG INDICATION; DRUG MECHANISM; DRUG PENETRATION; DRUG SAFETY; DRUG STRUCTURE; DRUG UTILIZATION; ELDERLY CARE; ENZYME INHIBITION; ESCHERICHIA COLI; FOOD AND DRUG ADMINISTRATION; GRAM NEGATIVE BACTERIUM; HAEMOPHILUS INFLUENZAE; HAEMOPHILUS PARAINFLUENZAE; HEADACHE; HEART ATRIUM FIBRILLATION; HEART VENTRICLE TACHYCARDIA; HOSPITAL INFECTION; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; IN VITRO STUDY; INJECTION SITE PAIN; INSOMNIA; KIDNEY DYSFUNCTION; KLEBSIELLA PNEUMONIAE; LEGIONELLA PNEUMOPHILA; MINIMUM INHIBITORY CONCENTRATION; MORAXELLA CATARRHALIS; MORTALITY; MYCOPLASMA PNEUMONIAE; NAUSEA AND VOMITING; PHOTOSENSITIVITY; POSTANTIBIOTIC EFFECT; PSEUDOMONAS AERUGINOSA; QT PROLONGATION; RESPIRATORY TRACT INFECTION; RESTLESSNESS; SEIZURE; SERRATIA MARCESCENS; SKIN INFECTION; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS; STREPTOCOCCUS PNEUMONIAE; SUPRAVENTRICULAR TACHYCARDIA; TENDON DISEASE; THRUSH; TORSADE DES POINTES; TREATMENT OUTCOME; TREMOR; URINARY TRACT INFECTION;

EID: 33744832470     PISSN: 1745509X     EISSN: 17455103     Source Type: Journal    
DOI: 10.2217/1745509X.2.3.371     Document Type: Article

References (58)

1. Dalhoff A, Ullmann U: Correlation between pharmacokinetics, pharmacodynamics and efficacy of antibacterial agents in animal models. Eur. J. Clin. Microbiol. Infect. Dis. 9, 479-487 (1990).
2. Wang JC: DNA topoisomerases. Annu. Rev. Biochem. 65, 635-692 (1996).
3. Wang JC, Lynch AS: Transcription and DNA supercoiling. Curr. Opin. Genet. Dev. 3, 764-768 (1993).
4. Pan XS, Fisher LM: Targeting of DNA gyrase in Streptococcus pneumoniae by sparfloxacin: selective targeting of gyrase or topoisomerase IV by quinolones. Antimicrob. Agents Chemother. 41, 471-474 (1997).
5. Zechiedrich EL, Cozzarelli NR: Roles of topoisomerase IV and DNA gyrase in DNA unlinking during replication in Escherichia coli. Genes Dev. 9, 2859-2869 (1995).
6. Kato J, Suzuki H, Ikeda H: Purification and characterization of DNA topoisomerase IV in Escherichia coli. J. Biol. Chem. 267, 25676-25684 (1992).
7. Blondeau JM: Fluoroquinolones: mechanism of action, classification, and development of resistance. Surv. Ophthalmol. 49(Suppl. 2), S73-S78 (2004).
8. Hooper DC: Mechanisms of action of antimicrobials: focus on fluoroquinolones. Clin. Infect. Dis 32(Suppl. 1), S9-S15 (2001).
9. Hooper DC: Emerging mechanisms of fluoroquinolone resistance. Emerging Infect. Dis. 7, 337-341 (2001).
10. Sierra JM, Cabeza JG, Ruiz Chaler M et al.: The selection of resistance to and the mutagenicity of different fluoroquinolones in Staphyloccus aureus and Streptococcus pneumoniae. Clin. Microbiol. Infect. 11, 750-758 (2005).
11. Hooper DC: Fluoroquinolone resistance among Gram-positive cocci. Lancet Infect. Dis. 2, 530-538 (2002).
12. Noreddin AM, Hoban DJ, Zhanel GG: Comparison of gatifloxacin and levofloxacin administered at various dosing regimens to hospitalised patients with community-acquired pneumonia: pharmacodynamic target attainment study using North American surveillance data for Streptococcus pneumoniae. Int. J. Antimicrob. Agents 26, 120-125 (2005).
13. MacDougall C, Harpe SE, Powell JP, Johnson CK, Edmond MB, Polk RE: Pseudomonas aeruginosa, Staphylococcus aureus and fluoroquinolone use. Emerging Infect. Dis. 11, 1197-1204 (2005).
14. Dalhoff A, Schmitz F-J: In vitro antibacterial activity and pharmacodynamics of new quinolones. Eur. J. Clin. Microbiol. Infect. Dis. 22, 203-221 (2003).
15. Hoogkamp-Korstanje JA: In-vitro activities of ciprofloxacin, levofloxacin, lomefloxacin, ofloxacin, pefloxacin, sparfloxacin and trovafloxacin against gram-positive and gram-negative pathogens from respiratory tract infections. J. Antimicrob. Chemother. 40, 427-431 (1997).
16. Jones RN, Sader HS, Beach ML: Contemporary in vitro spectrum of activity summary for antimicrobial agents tested against 18569 strains non-fermentative Gram-negative bacilli isolated in the SENTRY Antimicrobial Surveillance Program (1997-2001). Int. J. Antimicrob. Agents 22, 551-556 (2003).
17. Reinert RR, Reinert S, van der Linden M, Cil MY, Al-Lahham A, Appelbaum P: Antimicrobial susceptibility of Streptococcus pneumoniae in eight European countries from 2001 to 2003. Antimicrob. Agents Chemother. 49, 2903-2913 (2005).
18. Yamaguchi K, Ohno A: Investigation of the susceptibility trends in Japan to fluoroquinolones and other antimicrobial agents in a nationwide collection of clinical isolates: a longitudinal analysis from 1994 to 2002. Diagn. Microbiol. Infect. Dis. 52, 135-143 (2005).
19. Mikamo H, Kawazoe K, Sato Y, Izumi K, Tamaya T: Therapeutic effects of a new quinolone, DU-6859a, on polymicrobial infections in a newly designed model of rat uterine endometritis. J. Antimicrob. Chemother. 41, 131-133 (1998).
20. Montanari MP, Mingoia M, Marchetti F, Varaldo PE: In vitro activity of levofloxacin against gram-positive bacteria. Chemotherapy 45, 411-417 (1999).
21. Zhanel GG, Noreddin AM: Pharmacokinetics and pharmacodynamics of the new fluoroquinolones: focus on respiratory infections. Curr. Opin. Pharmacol. 1, 459-463 (2001).
22. Lacy MK, Lu W, Xu X et al.: Pharmacodynamic comparisons of levofloxacin, ciprofloxacin, and ampicillin against Streptococcus pneumoniae in an in vitro model of infection. Antimicrob. Agents Chemother. 43, 672-677 (1999).
23. Lister PD: Pharmacodynamics of 750 mg and 500 mg doses of levofloxacin against ciprofloxacin-resistant strains of Streptococcus pneumoniae. Diagn. Microbiol. Infect. Dis. 44, 43-49 (2002).
24. Noreddin AM, Marras TK, Sanders K, Chan CK, Hoban DJ, Zhanel GG: Pharmacodynamic target attainment analysis against Streptococcus pneumoniae using levofloxacin 500 mg, 750 mg and 1000 mg once daily in plasma (P) and epithelial lining fluid (ELF) of hospitalized patients with community acquired pneumonia (CAP). Int. J. Antimicrob. Agents 24, 479-484 (2004).
25. Hoban D, Baquero F, Reed V, Felmingham D: Demographic analysis of antimicrobial resistance among Streptoccus pneumoniae: worldwide results from PROTEKT 1999-2000. Int. J. Infect. Dis. 9, 262-273 (2005).
26. Drusano GL, Preston SL, Fowler C, Corrado M, Weisinger B, Kahn J: Relationship between fluoroquinolone area under the curve: minimum inhibitory concentration ratio and the probability of eradication of the infecting pathogen, in patients with nosocomial pneumonia. J. Infect. Dis. 189, 1590-1597 (2004).
27. Biedenbach DJ, Moet GJ, Jones RN: Occurrence and antimicrobial resistance pattern comparisons among bloodstream infection isolates from the SENTRY Antimicrobial Surveillance Program (1997-2002). Diagn. Microbiol. Infect. Dis. 50, 59-69 (2004).
28. Levaquin® package insert. Ortho McNeil Pharmaceutical Corporation, Raritan, NJ, USA (2005).
29. File TM Jr, Segreti J, Dunbar L et al.: A multicenter, randomized study comparing the efficacy and safety of intravenous and/or oral levofloxacin versus ceftriaxone and/or cefuroxime axetil in treatment of adults with community-acquired pneumonia. Antimicrob. Agents Chemother. 41, 1965-1972 (1997).
30. Dunbar LM, Wunderink RG, Habib MP et al.: High-dose, short-course levofloxacin for community-acquired pneumonia: a new treatment paradigm. Clin. Infect. Dis. 37, 752-760 (2003).
31. Shorr AF, Zadeikis N, Khashab MM, Tennenberg AM, Wes Ely E: Levofloxacin 750-mg, 5-day therapy for community-acquired pneumonia. Outcomes in the elderly American Thoracic Society International Conference. Orlando, FL, USA (2004) (Abstract 505).
32. Fogarty C, Siami G, Kohler R et al.: Multicenter open-label randomized study to compare the safety and efficacy of levofloxacin versus ceftriaxone sodium and erythromycin followed by clarithromycin and amoxicillin-clavulanate in the treatment of serious community-acquired pneumonia in adults. Clin. Infect. Dis. 38, S16-S23 (2004).
33. Anzueto A, Niederman MS, Pearle J et al.: Community-acquired pneumonia recovery in the elderly (CAPRIE): efficacy and safety of moxifloxacin therapy versus that of levofloxacin therapy. Clin. Infect. Dis. 42, 73-81 (2006).
34. Zervos M, Mandell LA, Vrooman PS et al.: Comparative efficacies and tolerabilities of intravenous azithromycin plus ceftriaxone and intravenous levofloxacin with stepdown oral therapy for hospitalized patients with moderate to severe community-acquired pneumonia. Treat. Respir. Med. 3, 329-336 (2004).
35. Leroy O, Saux P, Bedos J-P, Caulin E: Comparison of levofloxacin and cefotaxime combined with ofloxacin for ICU patients with community-acquired pneumonia who do not require vasopressors. Chest 128, 172-183 (2005).
36. Sabria M, Pedro-Botet ML, Gomez J et al.: Fluoroquinolones vs macrolides in the treatment of legionnaires disease. Chest 128, 1401-1405 (2005).
37. Mykietiuk A, Carralà J, Fernández-Sabé N et al.: Clinical outcomes for hospitalized patients with Legionella pneumonia in the antigenuria era: the influence of levofloxacin therapy. Clin. Infect. Dis. 40, 794-799 (2005).
38. Blázquez Garrido RM, Espinosa Parra FJ, Alemany Francés L et al.: Antimicrobial chemotherapy for Legionnaires disease: levofloxacin versus macrolides. Clin. Infect. Dis. 40, 800-806 (2005).
39. West M, Boulanger BR, Fogarty C et al.: Levofloxacin compared with imipenem/cilastatin followed by ciprofloxacin in adult patients with nosocomial pneumonia: a multicenter, prospective, randomized, open-label study. Clin. Ther. 25, 485-506 (2003).
40. Centers for Disease Control and Prevention: Pneumonia and influenza death rates United States. MMWR Morb. Mortal. Wkly Rep. 535-537 (1995).
41. Fein AM: Pneumonia in the elderly: overview of diagnostic and therapeutic approaches. Clin. Infect. Dis. 28, 726-729 (1999).
42. El-Solh AA, Pietrantoni C, Bhat A et al.: Microbiology of severe aspiration pneumonia in institutionalized elderly. Am. J. Respir. Crit. Care Med. 167, 1650-1654 (2003).
43. Niederman MS, Mandell LA, Anzueto A et al.: Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention. Am. J. Respir. Crit. Care Med. 163, 1730-1754 (2001).
44. Mandell LA, Bartlett JG, Dowell SF, File TM Jr, Mosher DM, Whitney C: Update of Practice Guidelines for the management of community-acquired pneumonia in immunocompetent adults. Clin. Infect. Dis. 37, 1405-1433 (2003).
45. BTS Guidelines for the management of community acquired pneumonia in adults. Thorax 56(Suppl. 4), S1-S64 (2001).
46. Mandell LA, Marrie TJ, Grossman RF, Chow AW, Hyland RH: Canadian guidelines for the initial management of community-acquired pneumonia: an evidence-based update by the Canadian Infectious Diseases Society and the Canadian Thoracic Society. The Canadian Community-Acquired Pneumonia Working Group. Clin. Infect. Dis. 31, 383-421 (2000).
47. Goldberg J, Owens RC Jr: Optimizing antimicrobial dosing in the critically ill patient. Curr. Opin. Crit. Care 8, 435-440 (2002).
48. Nicolle LE: Quinolones in the aged. Drugs 58(Suppl. 2), 49-51 (1999).
49. Stahlmann R, Lode H: Fluoroquinolones in the elderly: safety considerations. Drugs Aging 20, 289-302 (2003).
50. Muto CA, Pokrywka M, Shutt K et al.: A large outbreak of Clostridium difficile-associated disease with an unexpected proportion of deaths and colectomies at a teaching hospital following increased fluoroquinolone use. Infect. Control Hosp. Epidemiol. 26, 273-280 (2005).
51. McCusker ME, Harris AD, Perencevich E, Roghmann M-C: Fluoroquinolone use and Clostridium difficile-associated diarrhea. Emeging Infect. Dis. 9, 730-733 (2003).
52. Edlund C, Nord CE: Effect of quinolones on intestinal ecology. Drugs 58 (Suppl. 2), 65-70 (1999).
53. Cappelletty DM, Spivey M, Khashab MM, Kahn JB: The safety of levofloxacin 750 mg in elderly patients with community-acquired respiratory tract infections. American Thoracic Society International Meeting San Diego, CA, USA (2005) (Abstract 4241).
54. Cely CM, Arora P, Quartin AA, Kett DH, Schein RM: Relationship of baseline glucose homeostasis to hyperglycemia during medical critical illness. Chest 126, 879-887 (2004).
55. Kagansky N, Levy S, Rimon E et al.: Hypoglycemia as a predictor of mortality in hospitalized elderly patients. Arch. Intern. Med. 163, 1825-1829 (2003).
56. Shilo S, Berezovsky S, Friedlander Y, Sonnenblick M: Hypoglycemia in hospitalized nondiabetic older patients. J. Am. Geriatr. Soc. 46, 978-982 (1998).
57. Mohr JF, McKinnon PS, Peymann PJ, Kenton I, Septimus E, Okhuysen PC: A retrospective, comparative evaluation of dysglycemias in hospitalized patients receiving gatifloxacin, levofloxacin, ciprofloxacin, or ceftriaxone. Pharmacotherapy 25, 1303-1309 (2005).
58. Graumlich JF, Habis S, Avelino RR et al.: Hypoglycemia in inpatients after gatifloxacin or levofloxacin therapy: nested case-control study. Pharmacotherapy 25, 1296-1302 (2005).